Brain Imaging Biomarkers in Patients With Brain Metastasis

Status Recruiting

Clinical Trial Summary

A biomarker is a measurable indicator of the severity or presence of some disease state. In this study, brain metastases patients who will be receiving radiation treatment, will undergo CT (Computed Tomography) and MRI (Magnetic Resonance Imaging) scans prior to and after radiation treatment to measure these biomarkers. This is a single-center phase II study to validate the predictive abilities of biomarkers, in terms of determining how patients will respond to radiation treatment.

Clinical Trial Description

Advances in medical imaging can provide useful information to guide and look at the response to treatment. Previous studies suggest early changes in the tumor after radiation treatment may be detectable using special MRI (Magnetic Resonance Imaging), and CT (Computed Tomography) scans. A biomarker is a measureable indicator of the severity or presence of some disease state. Previous studies suggest that the change in several imaging biomarkers can predict who will respond to radiation treatment. In this study, patients will undergo CT and MRI scans prior to and after radiation treatment to measure these biomarkers. The purpose of this study is to validate the predictive abilities of biomarkers in terms of determining how patients will respond to radiation treatment. This is a single-center phase II study, which will be conducted at the Princess Margaret Cancer Center. The study will be enrolling up to a total of 90 patients who will be receiving radiation treatment for brain metastases. Patients will be asked to participate within this study for 2 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04197297
Study type	Interventional
Source	University Health Network, Toronto
Contact	David Shultz, M.D., Ph. D
Phone	416-946-6899
Email	david.shultz@rmp.uhn.on.ca
Status	Recruiting
Phase	Phase 2
Start date	October 5, 2021
Completion date	June 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05428852` - Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases	N/A
Recruiting	`NCT05559853` - Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
Recruiting	`NCT05689619` - SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)	N/A
Recruiting	`NCT04397978` - Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases
Terminated	`NCT04434560` - Neoadjuvant Immunotherapy in Brain Metastases	Phase 2
Active, not recruiting	`NCT05095766` - Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis
Recruiting	`NCT05012254` - Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases	Phase 2
Recruiting	`NCT05789589` - Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases	Phase 1/Phase 2
Recruiting	`NCT06280300` - Multi-disciplinary Care for Brain Metastases	N/A
Recruiting	`NCT06047379` - Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis	Phase 1/Phase 2
Completed	`NCT03896555` - Intrafractional Head Movement During Radiosurgery
Terminated	`NCT03789149` - Focal Intraoperative Radiotherapy of Brain Metastases	Phase 2
Recruiting	`NCT04343157` - UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases	Phase 2
Recruiting	`NCT04711824` - Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases	Phase 1/Phase 2
Recruiting	`NCT05793489` - Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin	N/A
Recruiting	`NCT04461418` - Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases	Phase 2
Recruiting	`NCT03818386` - Radiotherapy of Multiple Brain Metastases Using AGuIX®	Phase 2
Active, not recruiting	`NCT05087095` - Managing Distress in Malignant Brain Cancer	N/A
Recruiting	`NCT04396717` - Safety Study of Pritumumab in Brain Cancer	Phase 1
Recruiting	`NCT06231186` - a Feasibility Study of iHD-SRT for BM	N/A